Literature DB >> 21519542

Uncontrolled self-medication with venlafaxine in a patient with major depressive disorder.

Ji-Hye Song1, Bum-Hee Yu, Dongsoo Lee, Se Chang Yoon, Hong Jin Jeon.   

Abstract

Antidepressants are known to have no significant ability to cause addiction. However, a recent study showed many individuals with mood disorders self-medicated with antidepressants to relieve symptoms. We report here a male physician, diagnosed five years ago with major depressive disorder, with insomnia, anxiousness, and chest heaviness. He began self-medicating with 150 mg of venlafaxine daily, without any monitoring. During his most recent severe depressive episode, he was taking up to 1,500 mg of venlafaxine daily. Without this medication, he experienced discontinuation syndrome, which included severe anxiety, chest heaviness, and breathing difficulty, and which he judged as indicating a more severely depressed state. He also experienced overdose symptoms, such as hypertension and tachycardia. He attempted suicide with drugs that he possessed. In conclusion, careful monitoring is needed when treating patients with venlafaxine, because its discontinuation syndrome is similar to symptoms of major depressive disorder, and suicidality may result from an overdose.

Entities:  

Keywords:  Discontinuation syndrome; Major depressive disorder; Suicide attempt; Venlafaxine

Year:  2010        PMID: 21519542      PMCID: PMC3079191          DOI: 10.4306/pi.2011.8.1.74

Source DB:  PubMed          Journal:  Psychiatry Investig        ISSN: 1738-3684            Impact factor:   2.505


  16 in total

1.  Antidepressant withdrawal symptoms-telephone calls to a national medication helpline.

Authors:  David Taylor; Suzanne Stewart; Anne Connolly
Journal:  J Affect Disord       Date:  2006-06-22       Impact factor: 4.839

Review 2.  Monoamine depletion studies: implications for antidepressant discontinuation syndrome.

Authors:  Pedro L Delgado
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

3.  Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms.

Authors:  Aytekin Sir; Russell F D'Souza; Sukru Uguz; Tom George; Simavi Vahip; Malcolm Hopwood; Andrew J Martin; William Lam; Tal Burt
Journal:  J Clin Psychiatry       Date:  2005-10       Impact factor: 4.384

Review 4.  SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.

Authors:  Stephen M Stahl; Meghan M Grady; Chantal Moret; Mike Briley
Journal:  CNS Spectr       Date:  2005-09       Impact factor: 3.790

Review 5.  Do antidepressants have any potential to cause addiction?

Authors:  P Haddad
Journal:  J Psychopharmacol       Date:  1999       Impact factor: 4.153

6.  Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Authors:  Christine J Truman; Joseph F Goldberg; S Nassir Ghaemi; Claudia F Baldassano; Stephen R Wisniewski; Ellen B Dennehy; Michael E Thase; Gary S Sachs
Journal:  J Clin Psychiatry       Date:  2007-10       Impact factor: 4.384

7.  Prevalence of substance use among US physicians.

Authors:  P H Hughes; N Brandenburg; D C Baldwin; C L Storr; K M Williams; J C Anthony; D V Sheehan
Journal:  JAMA       Date:  1992-05-06       Impact factor: 56.272

8.  The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study.

Authors:  Aung Tint; Peter M Haddad; Ian M Anderson
Journal:  J Psychopharmacol       Date:  2008-05       Impact factor: 4.153

Review 9.  Cardiovascular safety in depressed patients: focus on venlafaxine.

Authors:  J P Feighner
Journal:  J Clin Psychiatry       Date:  1995-12       Impact factor: 4.384

10.  How patients with depressive symptoms view their condition: a qualitative study.

Authors:  Charles S Cornford; Angela Hill; Joe Reilly
Journal:  Fam Pract       Date:  2007-07-13       Impact factor: 2.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.